Recombinant CD19 (Inebilizumab Biosimilar) anticorps

N° du produit ABIN7488071

Cet anticorps anti-CD19 (Inebilizumab Biosimilar) est un anticorps Mammalian Cells Monoclonal détectant CD19 (Inebilizumab Biosimilar) dans ELISA. Adapté pour Humain.

Aperçu rapide pour Recombinant CD19 (Inebilizumab Biosimilar) anticorps (ABIN7488071)

Antigène: CD19 (Inebilizumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Mammalian Cells

Clonalité: Monoclonal

Conjugué: Cet anticorp CD19 (Inebilizumab Biosimilar) est non-conjugé

Application: ELISA

Classe de qualité: Research Grade

Détail du produit anti-CD19 (Inebilizumab Biosimilar) anticorps

Expression System: Mammalian cells

Fonction: Inebilizumab Biosimilar - Anti-CD19 mAb

Attributs du produit: Antibody Type: IgG1-kappa

Purification: Recombinant antibody expressed in mammalien cells and purified.

Isotype: IgG1 kappa

Information d'application

Restrictions: For Research Use only

Stockage

Buffer: PBS pH 7.5

Stock: -80 °C

Stockage commentaire: store at -80°C

Détails sur CD19 (Inebilizumab Biosimilar)

Antigène: CD19 (Inebilizumab Biosimilar)

Classe de substances: Biosimilar

Sujet: MEDI-551
Inebilizumab is a humanized afucosylated monoclonal IgG1 antibody that targets the broadly expressed B-cell surface antigen CD19. Inebilizumab is cytolytic, which may be usefull to treat neuromyelitis optica spectrum disorder (NMOSD)through B-cell depletion.

Numéro CAS: 1299440-37-1